How Much Does Tirosint Cost in Vermont in 2026?

Vermont Retail Pricing for Tirosint in 2026

The average cash-pay price for Tirosint at Vermont retail pharmacies in 2026 sits at approximately $230 per month. That figure tracks closely with IBSA's manufacturer list price and applies across standard retail chains in Burlington, Montpelier, Rutland, and smaller communities throughout the state.

Tirosint is a gel cap formulation of levothyroxine sodium, FDA-approved for hypothyroidism. Unlike traditional levothyroxine tablets (Synthroid, Levoxyl, generics), Tirosint contains only four inactive ingredients: gelatin, glycerin, sorbitol, and water. That minimal excipient profile makes it a preferred option for patients with absorption issues or sensitivities to dyes, lactose, gluten, or other fillers found in standard tablets. A 2014 study by Vita et al. demonstrated that the liquid/gel cap formulation of levothyroxine improved TSH normalization in patients with gastric disorders compared to tablet levothyroxine [1].

Price can vary by $10 to $25 depending on the specific pharmacy and dose strength. Higher microgram capsules (100 mcg, 125 mcg, 150 mcg) sometimes cost marginally more than lower-dose versions (13 mcg, 25 mcg, 50 mcg), though many pharmacies price them identically. Patients filling without insurance should call at least two pharmacies before purchasing. The GoodRx and RxSaver platforms occasionally list Vermont-specific coupons, but most still land in the $180 to $240 range for a 30-day supply.

Vermont Medicaid Coverage for Tirosint

Vermont Medicaid does cover Tirosint. Prior authorization is required. That means a prescriber must submit documentation showing why the gel cap formulation is medically necessary over generic levothyroxine tablets before Medicaid will approve the claim.

The most common clinical justifications that Vermont Medicaid accepts include documented malabsorption (celiac disease, inflammatory bowel disease, gastric bypass history), intolerance or allergy to excipients in tablet formulations, and persistent TSH instability despite adequate tablet dosing and confirmed adherence. The American Thyroid Association's 2014 guidelines recommend considering alternative levothyroxine formulations when absorption is impaired by gastrointestinal conditions or concurrent medications like proton pump inhibitors and calcium supplements [2].

The PA process typically takes 3 to 7 business days. Prescribers can expedite the process by including recent lab values (TSH, free T4), a medication history showing trial and failure on generic tablets, and relevant GI diagnoses with ICD-10 codes. If the initial PA is denied, Vermont Medicaid allows a formal appeal with supporting clinical documentation.

Patients enrolled in Vermont's Dr. Dynasaur program (covering children and pregnant women) follow the same PA pathway. Pregnant patients with absorption concerns may receive faster approval given the clinical urgency of maintaining euthyroid status during gestation. Untreated maternal hypothyroidism is associated with adverse neurodevelopmental outcomes, as established by the Haddow et al. study published in the New England Journal of Medicine [3].

Which Private Insurance Plans Cover Tirosint in Vermont?

Most major insurers operating in Vermont place Tirosint on a specialty or non-preferred brand tier. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna all list Tirosint on their formularies, but typically as Tier 3 (non-preferred brand) or Tier 4. Copays at these tiers range from $50 to $90 per month.

Step therapy is common. Insurers generally require a 30- to 90-day trial of generic levothyroxine tablets before approving Tirosint. Some plans also require documentation of a specific clinical reason the tablet formulation is inadequate.

Patients on high-deductible health plans should expect to pay the full cash price ($230) until meeting their deductible. After meeting the deductible, coinsurance rates of 20% to 40% are typical, bringing the monthly cost to roughly $46 to $92.

Self-funded employer plans (ERISA plans) follow their own formulary rules and may not match the coverage policies of Vermont's state-regulated individual and small-group market plans. Patients should verify coverage by calling the number on the back of their insurance card and requesting a formulary exception if Tirosint is not covered.

The IBSA Savings Card: How It Works in Vermont

IBSA, the manufacturer of Tirosint, offers a savings card program that can reduce monthly copays for commercially insured patients. The card is not valid for patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligible patients can enroll online through the IBSA website. The savings card typically covers $50 to $100 off per prescription fill, though the exact discount varies by plan year and promotional period. Some patients report paying as little as $25 per month after applying the card to their existing insurance copay.

Restrictions apply. The card has an annual maximum benefit (often $1,200 to $1,800 per year) and may expire at the end of the calendar year, requiring re-enrollment. Vermont does not have state-level legislation restricting manufacturer copay assistance cards for brand-name drugs, so the IBSA card functions here without additional regulatory barriers.

Cash-pay patients (those without any insurance) may also benefit from the card, though the discount is typically smaller for uninsured fills compared to insured copay reductions. Patients should ask the pharmacist to run both the insurance claim and the savings card simultaneously to determine the lowest out-of-pocket price.

Compounded Levothyroxine in Vermont: Legal Status and Pricing

Compounded levothyroxine liquid or gel cap preparations are legal in Vermont when dispensed by a licensed 503A compounding pharmacy pursuant to a valid patient-specific prescription. The FDA's guidance on 503A compounding permits state-licensed pharmacies to compound medications for individual patients when a prescriber determines that a commercially available product does not meet a patient's medical needs [4].

Several Vermont compounding pharmacies and multi-state 503A pharmacies shipping into Vermont offer compounded levothyroxine. Pricing varies significantly. Some telehealth platforms bundle compounded levothyroxine into membership or subscription models at no additional per-prescription cost, effectively bringing the monthly medication expense to $0.

Patients considering compounded levothyroxine should evaluate three factors before switching from brand Tirosint. First, verify that the compounding pharmacy holds a current Vermont Board of Pharmacy license or is registered to ship into the state. Second, confirm the pharmacy follows USP 795 and USP 797 standards for non-sterile and sterile compounding, respectively. Third, understand that compounded medications do not undergo the same FDA bioequivalence testing as commercially manufactured drugs. While the active ingredient (levothyroxine sodium) is identical, variations in absorption may occur between compounders. Patients switching from Tirosint to a compounded formulation should have TSH and free T4 rechecked 6 to 8 weeks after the switch, consistent with ATA monitoring recommendations [2].

A compounded preparation may be particularly appropriate for patients who need a dose not commercially available (e.g., 37 mcg, 62 mcg), those requiring a dye-free liquid formulation for pediatric use, or individuals whose insurance will not cover Tirosint and who cannot afford the $230 monthly cash price.

Tirosint via Telehealth in Vermont

Telehealth prescribing of Tirosint is permitted in Vermont. The state has maintained its expanded telehealth policies enacted during the COVID-19 public health emergency, and Vermont law allows prescribers to establish a patient-provider relationship via audio-video telemedicine for most non-controlled substances.

A Vermont-licensed physician, nurse practitioner, or physician assistant can evaluate a patient remotely, review thyroid labs, and prescribe Tirosint electronically to any Vermont pharmacy. The prescription is transmitted via e-prescribing (EPCS is required only for controlled substances, which levothyroxine is not).

Several national telehealth platforms serve Vermont patients for thyroid management. Patients should confirm that the telehealth provider is licensed in Vermont specifically, as prescribing across state lines without proper licensure violates both state pharmacy law and medical board regulations. The Federation of State Medical Boards has documented the rapid expansion of interstate telehealth compacts, but Vermont's participation varies by profession [5].

For patients combining telehealth with compounded levothyroxine, the prescriber writes the prescription specifying the compound formula, and the patient selects a 503A pharmacy that ships to Vermont. This model eliminates geographic barriers for patients in rural parts of the state, including the Northeast Kingdom, where endocrinology specialists are scarce.

Cheapest Ways to Get Tirosint in Vermont

Cost-conscious patients have several options to reduce Tirosint spending in Vermont. The table below ranks them from lowest to highest typical monthly out-of-pocket cost.

Compounded levothyroxine through a subscription telehealth platform can bring monthly cost to $0 when the medication is bundled into the consultation fee. The IBSA savings card combined with commercial insurance typically yields $25 to $75 per month. Insurance with PA approval on a preferred brand tier runs $30 to $50. A GoodRx or RxSaver coupon at a Vermont retail pharmacy brings cash-pay pricing to $180 to $220. Paying full retail without any discount or insurance costs $230.

Patients should also ask their prescriber about Tirosint-SOL, the liquid levothyroxine solution also manufactured by IBSA. Tirosint-SOL may be priced differently than the gel cap and could be covered under different formulary tiers. The clinical data supporting liquid levothyroxine absorption in malabsorption states applies to both formulations, as Vita et al. demonstrated improved TSH normalization with the liquid formulation specifically in patients taking proton pump inhibitors [1].

Vermont-Specific Discount Programs

Vermont does not operate a state-specific pharmaceutical assistance program for thyroid medications. The Vermont Health Connect marketplace plans follow ACA formulary requirements, which include coverage for medically necessary brand-name medications when generics are clinically inappropriate.

The Vermont 211 resource line connects residents to social services including medication assistance programs [6]. Patients who meet income thresholds (typically below 200% of the federal poverty level) may qualify for manufacturer patient assistance programs offered directly by IBSA. These programs are separate from the savings card and provide Tirosint at no cost to qualifying uninsured or underinsured patients.

Community health centers operating under the 340B Drug Pricing Program, including several Federally Qualified Health Centers in Vermont, may access Tirosint at a reduced acquisition cost. Patients receiving care at a 340B-eligible site should ask whether the pharmacy can pass along 340B pricing. The Health Resources and Services Administration maintains the 340B database of eligible entities [7].

Vermont pharmacies may also offer auto-refill discount programs or loyalty pricing for cash-pay customers. Independent pharmacies in particular sometimes negotiate lower acquisition costs through purchasing cooperatives like EPIC Pharmacies or Good Neighbor Pharmacy and pass a portion of those savings to the patient.

When to Choose Tirosint Over Generic Levothyroxine Tablets

The clinical case for Tirosint rests on absorption reliability. Generic levothyroxine tablets contain binders, fillers, and dyes that can interfere with absorption in certain patient populations. The Vita et al. (2014) study in Endocrine showed that patients with impaired gastric acid secretion achieved TSH normalization rates of 78% on liquid/gel cap levothyroxine versus 47% on tablets (P<0.001) [1].

Patients most likely to benefit from the gel cap or liquid formulation include those with celiac disease, atrophic gastritis, H. pylori infection, or post-bariatric surgery anatomy. Patients taking medications that interfere with tablet levothyroxine absorption (calcium carbonate, ferrous sulfate, proton pump inhibitors, cholestyramine) may also see improved thyroid hormone levels with the gel cap formulation, since the liquid/gel matrix bypasses the dissolution step that these medications disrupt.

Dr. Francesco Centanni, whose research group has published extensively on levothyroxine absorption, noted: "The gel capsule formulation eliminates the dissolution-dependent step of absorption, making it inherently less susceptible to interference from gastric pH changes and food timing" [1].

For patients without absorption concerns, generic levothyroxine tablets remain effective and are available for $4 to $15 per month at most Vermont pharmacies. The cost difference between generic tablets and brand Tirosint ($215+ per month) is difficult to justify without a documented clinical need.

Prescribers in Vermont should recheck TSH 6 to 8 weeks after any formulation switch, adjust the dose to maintain TSH within the patient's target range (typically 0.5 to 2.5 mIU/L for most adults, per ATA guidelines), and document the clinical rationale for Tirosint if prior authorization is needed [2].